Ministerio de Industria, Turismo y Comercio LogoMinisterior
 

Alerta

Resultados 61 resultados
LastUpdate Última actualización 15/03/2025 [07:49:00]
pdfxls
Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days
previousPage Resultados 50 a 61 de 61  

Improved Gamma-Secretase Inhibitor Screening Assays

NºPublicación:  US2025027956A1 23/01/2025
Solicitante: 
VIB VZW [BE]
KATHOLIEKE UNIV LEUVEN [BE]
VIB VZW,
Katholieke Universiteit Leuven
US_2025027956_A1

Resumen de: US2025027956A1

Current application relates to the field of neurodegenerative diseases. Specifically, the present invention relates to screening methods to identify therapeutic candidates for the prevention and/or treatment of Alzheimer's disease. More particularly, said candidates overcome endolysosomal dysfunction resulting from an accumulation of APP-carboxyterminal fragments.

COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE UTILIZING A TRANSCRIPTIONAL MASTER REGULATOR OF THE RETROMER COMPLEX

NºPublicación:  US2025027085A1 23/01/2025
Solicitante: 
THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK [US]
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
US_2025027085_A1

Resumen de: US2025027085A1

The present disclosure provides, inter alia, methods for treating neurodegenerative disease including Alzheimer's disease. Methods for restoring retromer complex function in a subject, methods for determining the progression of a neurodegenerative disease in a subject, and in vivo methods for identifying a DNA-binding profile of a dimeric transcription factor complex such as the retromer complex are also provided. Further provided are methods for restoring amyloid precursor protein (APP) homeostasis in a subject in need thereof, methods for restoring tau metabolism in a subject in need thereof, compositions and methods for preventing CREB3L2-ATF4 heterodimerization in a subject using such compositions, and methods for rescuing AP42-induced neuronal cell death in a subject using such compositions.

BCAA-Lowering Compounds for Prevention and/or Treatment of Alzheimer's Disease and Related Disorders

NºPublicación:  US2025025442A1 23/01/2025
Solicitante: 
TEXAS TECH UNIV SYSTEM [US]
Texas Tech University System
US_2025025442_A1

Resumen de: US2025025442A1

The present invention includes compositions and methods of treating CNS-related conditions, comprising: administering an effective amount of a compound that lowers the levels of one or more branched-chain amino acids (BCAAs) or metabolites thereof, or any pharmaceutically acceptable salt thereof, wherein the CNS-related conditions is selected from the group consisting of Alzheimer's disease and any related forms of dementia including vascular dementia, Lewy body dementia, frontotemporal dementia, Creutzfeldt-Jacob disease, Wernicke-Korsakoff disease, and Huntington's disease, Multiple sclerosis, Parkinson's disease, autism, Amyotrophic lateral sclerosis (ALS), Hereditary diffuse leukoencephalopathy with spheroids (HDLS) and epilepsy.

NON-PURIFIED CSF AND CSF-DERIVED EVS MARKERS FOR PATIENTS WITH ALZHEIMER'S, PARKINSON'S AND LEWY BODY DEMENTIA

NºPublicación:  WO2025016932A1 23/01/2025
Solicitante: 
VITO NV [BE]
UNIV ANTWERPEN [BE]
VITO NV,
UNIVERSITEIT ANTWERPEN
WO_2025016932_PA

Resumen de: WO2025016932A1

The present invention is directed to the field of dementia, providing non-purified CSF and CSF- derived EVs markers for differential dementia diagnosis in patients with Alzheimer's, Parkinson's and Lewy body dementia. It not only provides the markers, but equally the method in using said markers for differential dementia diagnosis amongst the aforementioned patients.

ANTIMICROBIAL PEPTIDES

NºPublicación:  WO2025019457A1 23/01/2025
Solicitante: 
EISAI R&D MAN CO LTD [JP]
SACHDEV PALLAVI [US]
EISAI R&D MANAGEMENT CO., LTD,
SACHDEV, Pallavi
WO_2025019457_PA

Resumen de: WO2025019457A1

Disclosed herein are methods of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD, based on presence of antimicrobial peptides (AMPs) at levels that differ from those in control individuals.

USE OF NEURONAL NITRIC OXIDE SYNTHASE INHIBITORS IN ALZHEIMER'S DISEASE

NºPublicación:  WO2025019870A1 23/01/2025
Solicitante: 
NORTHWESTERN UNIV [US]
NORTHWESTERN UNIVERSITY
WO_2025019870_PA

Resumen de: WO2025019870A1

Disclosed are neuronal nitric oxide synthase (nNOS) inhibitors for use in methods for reducing AβO-induced tau phosphorylation, reducing AβO formation and accumulation on neurons, and modulating neuronal nitric oxide synthase (nNOS).

METHOD AND KIT FOR DIAGNOSING ALZHEIMER'S DISEASE BASED ON THE DETECTION OF APOLIPOPROTEIN E

NºPublicación:  EP4495599A1 22/01/2025
Solicitante: 
UNIV MIGUEL HERNANDEZ DE ELCHE [ES]
CONSORCIO CENTRO DE INVESTIG BIOMEDICA EN RED [ES]
Universidad Miguel Hern\u00E1ndez de Elche,
Consorcio Centro de Investigaci\u00F3n Biom\u00E9dica en Red
EP_4495599_PA

Resumen de: EP4495599A1

The present invention relates to an in vitro method for the diagnosis of Alzheimer's disease, comprising the determination of an apolipoprotein E (ApoE)-based biomarker selected from the group consisting of: presence, amount, or concentration ApoE having a size of 34 kDa in an ApoE aggregate having a size of 100 kDa; ratio of ApoE dimers/monomers detected in a native electrophoresis assay; and presence of ApoE dimers detected in a native electrophoresis assay. The present invention also relates to a kit for diagnosing Alzheimer's disease comprising reagents for carrying out the method of the invention.

METHOD FOR MANUFACTURING FIBER OPTIC BASED PLASMONIC BIOSENSOR FOR DEMENTIA DIAGNOSIS AND BIOSENSOR MANUFACTURED THEREFROM

NºPublicación:  KR20250011594A 21/01/2025
Solicitante: 
단국대학교산학협력단

Resumen de: KR20250011594A

본 발명은 치매 진단을 위한 광섬유 기반의 플라즈모닉 바이오센서의 제작방법과 이로부터 제작된 바이오센서에 관한 것이다. 본 발명은 상기 바이오센서를 제작하기 위해 세 가지 전략을 수행하였다. 첫째로, 광섬유 표면에 고정되는 금속 나노입자의 밀도를 최적화하여 바이오센서의 감도를 최적화하였다. 둘째로, 금속 나노입자의 크기를 증가시키는 금속 덧씌움(Capping) 공정을 수행하여 금속 나노입자의 산란 효율을 증가시켰다. 셋째로, 광섬유 표면 중 금속 나노입자가 고정되지 않은 베어(Bare) 표면을 식각하여 배경 신호를 감소시켰다. 상기 세 가지 전략에 따라 바이오센서를 제작하였고, 알츠하이머의 생체 표지자인 아밀로이드 베타(Amyloid Beta)를 측정하였다. 본 발명에 따른 바이오센서는 종래보다 더 낮은 검출 한계, 더 빠른 진단 시간, 더 높은 정확성을 나타내었다.

IN VITRO POINT-OF-CARE ASSAY METHOD/PROCESS USING COMBINATION OF BIOACTIVATED NON-MAGNETIC AND MAGNETIC QUANTUM DOTS FOR RAPID IMMUNO-OPTOMAGNETIC DETECTION OF SERUM BIOMARKERS IN FREE SOLUTION

NºPublicación:  US2025020671A1 16/01/2025
Solicitante: 
SABANCI UNIV NANOTEKNOLOJI ARASTIRMA VE UYGULAMA MERKEZI [TR]
SABANCI UNIVERSITESI NANOTEKNOLOJI ARASTIRMA VE UYGULAMA MERKEZI
WO_2023128904_PA

Resumen de: US2025020671A1

A method for detecting risk biomarkers for chronic neurodegenerative disorder of central nervous system called Alzheimer's disease (AD) is provided. AD is the most common cause of dementia, and it is characterized by extracellular senile plaques formed by the accumulation of amyloid β (Aβ) proteins and aggregation of tau proteins into intracellular neurofibrillary tangles in central nervous system. The present invention aims at developing a novel PoC based multiple AD biomarkers detection assay and method, such as Aβ1-40/Aβ1-42, tau protein and BDNF using multi-colored highly luminescent, non-photo-bleaching quantum dots (QDs), which provides an affordable and accurate means for early diagnosis of MCI, AD or dementia at homes, hospitals or near the patient bedsides.

ASSAY METHODS AND USES THEREOF FOR SCREENING ALZHEIMER'S DISEASE TREATMENT COMPOUNDS

NºPublicación:  US2025020635A1 16/01/2025
Solicitante: 
THE TRUSTEES OF INDIANA UNIV [US]
The Trustees Of Indiana University

Resumen de: US2025020635A1

The present disclosure provides methods, assays, kits, and uses thereof for screening candidate therapeutics for their tendency to induce phagocytosis in a cell. In one aspect, the present disclosure provides a method of assaying a candidate compound for its tendency to induce phagocytosis in a cell, the method comprising: contacting the cells with the candidate compound; contacting the cells with a target ligand bound to a fluorescent phagocytosis vesicle reporter having a fluorophore emission wavelength; nuclear staining the cells with a DNA-specific fluorescent stain; and measuring the fluorescence amplitude of the fluorescent phagocytosis vesicle reporter. In another aspect, the present disclosure provides a cell-health assay for testing compounds for their potential for treating neurodegenerative disorders.

NON-PURIFIED CSF AND CSF-DERIVED EVS MARKERS FOR PATIENTS WITH ALZHEIMER`S, PARKINSON`S AND LEWY BODY DEMENTIA

Nº publicación: EP4492033A1 15/01/2025

Solicitante:

VITO NV [BE]
UNIV ANTWERPEN [BE]
VITO NV,
Universiteit Antwerpen

EP_4492033_PA

Resumen de: EP4492033A1

The present invention is directed to the field of dementia, providing non-purified CSF and CSF-derived EVs markers for differential dementia diagnosis in patients with Alzheimer's, Parkinson's and Lewy body dementia. It not only provides the markers, but equally the method in using said markers for differential dementia diagnosis amongst the aforementioned patients.

traducir